JP2017095457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017095457A5 JP2017095457A5 JP2016222861A JP2016222861A JP2017095457A5 JP 2017095457 A5 JP2017095457 A5 JP 2017095457A5 JP 2016222861 A JP2016222861 A JP 2016222861A JP 2016222861 A JP2016222861 A JP 2016222861A JP 2017095457 A5 JP2017095457 A5 JP 2017095457A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- drug
- drug conjugate
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000611 antibody drug conjugate Substances 0.000 claims 8
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940041181 antineoplastic drug Drugs 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims 2
- 206010034299 Penile cancer Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 206010047741 Vulval cancer Diseases 0.000 claims 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000002628 peritoneum cancer Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 201000005102 vulva cancer Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014017777 | 2014-01-31 | ||
| JP2014017777 | 2014-01-31 | ||
| JP2014168944 | 2014-08-22 | ||
| JP2014168944 | 2014-08-22 | ||
| JP2014227886 | 2014-11-10 | ||
| JP2014227886 | 2014-11-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016166850A Division JP6046301B1 (ja) | 2014-01-31 | 2016-08-29 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017003826A Division JP6105183B1 (ja) | 2014-01-31 | 2017-01-13 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2019002311A Division JP6665325B2 (ja) | 2014-01-31 | 2019-01-10 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017095457A JP2017095457A (ja) | 2017-06-01 |
| JP2017095457A5 true JP2017095457A5 (cg-RX-API-DMAC10.html) | 2018-03-01 |
| JP6466895B2 JP6466895B2 (ja) | 2019-02-06 |
Family
ID=53756672
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542503A Active JP5998289B2 (ja) | 2014-01-31 | 2015-01-28 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2016166850A Active JP6046301B1 (ja) | 2014-01-31 | 2016-08-29 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2016222861A Active JP6466895B2 (ja) | 2014-01-31 | 2016-11-16 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2017003826A Active JP6105183B1 (ja) | 2014-01-31 | 2017-01-13 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2019002311A Active JP6665325B2 (ja) | 2014-01-31 | 2019-01-10 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2020025886A Active JP6914380B2 (ja) | 2014-01-31 | 2020-02-19 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2021115436A Active JP7146031B2 (ja) | 2014-01-31 | 2021-07-13 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| JP2022149242A Active JP7467557B2 (ja) | 2014-01-31 | 2022-09-20 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| JP2024059913A Active JP7703727B2 (ja) | 2014-01-31 | 2024-04-03 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| JP2025107304A Pending JP2025138756A (ja) | 2014-01-31 | 2025-06-25 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542503A Active JP5998289B2 (ja) | 2014-01-31 | 2015-01-28 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2016166850A Active JP6046301B1 (ja) | 2014-01-31 | 2016-08-29 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017003826A Active JP6105183B1 (ja) | 2014-01-31 | 2017-01-13 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2019002311A Active JP6665325B2 (ja) | 2014-01-31 | 2019-01-10 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2020025886A Active JP6914380B2 (ja) | 2014-01-31 | 2020-02-19 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| JP2021115436A Active JP7146031B2 (ja) | 2014-01-31 | 2021-07-13 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| JP2022149242A Active JP7467557B2 (ja) | 2014-01-31 | 2022-09-20 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| JP2024059913A Active JP7703727B2 (ja) | 2014-01-31 | 2024-04-03 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| JP2025107304A Pending JP2025138756A (ja) | 2014-01-31 | 2025-06-25 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
Country Status (31)
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115960111A (zh) * | 2012-10-11 | 2023-04-14 | 第一三共株式会社 | 抗体－药物偶联物 |
| JP6130517B2 (ja) * | 2013-12-25 | 2017-05-17 | 第一三共株式会社 | 抗ｔｒｏｐ２抗体−薬物コンジュゲート |
| PL4212552T3 (pl) * | 2014-01-31 | 2025-03-17 | Daiichi Sankyo Company, Limited | Koniugat przeciwciało anty-her2-lek |
| ES2754348T3 (es) * | 2014-04-10 | 2020-04-17 | Daiichi Sankyo Co Ltd | Conjugado de (anticuerpo anti-HER2)-fármaco |
| US9808528B2 (en) | 2014-06-18 | 2017-11-07 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
| TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗ｈｅｒ２表位之單株抗體及其使用之方法 |
| IL290959B2 (en) | 2015-06-29 | 2023-04-01 | Daiichi Sankyo Co Ltd | Preparations containing antibody-drug conjugates and methods for their production |
| BR112019005247A2 (pt) * | 2016-10-07 | 2019-06-04 | Daiichi Sankyo Co Ltd | terapia para o câncer resistente a fármacos por meio de administração de conjugado de anticorpo anti-her2/fármaco |
| TW202508642A (zh) | 2016-12-12 | 2025-03-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途 |
| WO2018159582A1 (ja) * | 2017-02-28 | 2018-09-07 | 学校法人近畿大学 | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｅｇｆｒ－ｔｋｉ抵抗性の非小細胞肺癌の治療方法 |
| CN108653746B (zh) * | 2017-03-29 | 2021-04-27 | 北京键凯科技股份有限公司 | 一种多载药点、高载药配基药物偶联物 |
| CN118767159A (zh) | 2017-08-23 | 2024-10-15 | 第一三共株式会社 | 抗体-药物缀合物制剂及其冻干 |
| CN117838881A (zh) * | 2017-08-31 | 2024-04-09 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
| EP3677589B1 (en) | 2017-08-31 | 2025-11-26 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| BR112020023373A2 (pt) | 2018-05-18 | 2021-02-09 | Daiichi Sankyo Company, Limited | conjugado, composição, e, uso de um conjugado ou de uma composição |
| CN120501882A (zh) * | 2018-05-28 | 2025-08-19 | 第一三共株式会社 | 通过施用抗her2抗体-药物缀合物治疗her2突变的癌 |
| EP3801632A1 (en) | 2018-06-01 | 2021-04-14 | Eisai R&D Management Co., Ltd. | Splicing modulator antibody-drug conjugates and methods of use |
| KR20210038904A (ko) * | 2018-07-25 | 2021-04-08 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘쥬게이트의 효과적인 제조 방법 |
| TWI846717B (zh) * | 2018-07-27 | 2024-07-01 | 日商第一三共股份有限公司 | 辨識抗體-藥物結合物之藥物部位的蛋白質 |
| SG11202100947SA (en) * | 2018-07-31 | 2021-03-30 | Daiichi Sankyo Co Ltd | Treatment of metastatic brain tumor by administration of antibody-drug conjugate |
| CN110790840A (zh) | 2018-08-01 | 2020-02-14 | 三生国健药业（上海）股份有限公司 | 结合人her2的抗体、其制备方法和用途 |
| JP7458981B2 (ja) | 2018-08-06 | 2024-04-01 | 第一三共株式会社 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| US12312641B2 (en) | 2018-08-23 | 2025-05-27 | Daiichi Sankyo Company, Limited | Sensitivity marker for antibody-drug conjugate |
| KR20210066833A (ko) | 2018-09-26 | 2021-06-07 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 엑사테칸 유사체의 리간드-약물 접합체, 이를 위한 제조 방법, 및 이의 적용 |
| JP7408646B2 (ja) | 2018-09-30 | 2024-01-05 | ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド | 抗－ｂ７ｈ３抗体－エキサテカンアナログコンジュゲート及びその医薬用途 |
| SG11202106248XA (en) | 2018-12-11 | 2021-07-29 | Daiichi Sankyo Co Ltd | Combination of antibody-drug conjugate with parp inhibitor |
| US20220040324A1 (en) * | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| CN109824759A (zh) * | 2019-03-08 | 2019-05-31 | 联宁（苏州）生物制药有限公司 | 一种用于抗体药物偶联物的药物-连接子mc-mmaf的制备方法及其中间体 |
| LT3946464T (lt) | 2019-03-29 | 2022-11-10 | Medimmune Limited | Junginiai ir jų konjugatai |
| CN111686259B (zh) * | 2019-05-26 | 2023-08-08 | 成都百利多特生物药业有限责任公司 | 一种含sn38的抗体药物偶联物 |
| CN113766933B (zh) * | 2019-06-28 | 2024-09-06 | 上海复旦张江生物医药股份有限公司 | 一种抗体偶联药物、其中间体、制备方法及应用 |
| WO2021052402A1 (zh) * | 2019-09-18 | 2021-03-25 | 四川百利药业有限责任公司 | 一种喜树碱衍生物及其偶联物 |
| KR20220115566A (ko) | 2019-11-15 | 2022-08-17 | 시아겐 인크. | 항-her2 항체-약물 접합체와 조합된 투카티닙으로 her2 양성 유방암을 치료하는 방법 |
| JP7720305B2 (ja) | 2019-12-12 | 2025-08-07 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗クローディン抗体薬物複合体及びその医薬用途 |
| CN118453897A (zh) | 2019-12-16 | 2024-08-09 | 江苏恒瑞医药股份有限公司 | 抗cea抗体-依喜替康类似物偶联物及其医药用途 |
| CA3168260A1 (en) | 2020-01-22 | 2021-07-29 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof |
| WO2021190581A1 (zh) * | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | 一种含抗体药物偶联物的药物组合物及其用途 |
| KR20220157425A (ko) * | 2020-03-25 | 2022-11-29 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항체 약물 접합체의 제조 방법 |
| US20230140397A1 (en) | 2020-03-25 | 2023-05-04 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-psma antibody-exatecan analogue conjugate and medical use thereof |
| KR102857257B1 (ko) * | 2020-06-12 | 2025-09-10 | 애피컬 몰레큘러 바이오테크 씨오., 엘티디. | 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 카보네이트를 함유한 프테로스틸벤 아미노산의 신규 유사체 |
| WO2021260583A1 (en) * | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
| JP7794766B2 (ja) * | 2020-06-24 | 2026-01-06 | アストラゼネカ ユーケー リミテッド | 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ |
| TW202216209A (zh) * | 2020-06-24 | 2022-05-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及atm抑制劑之組合 |
| WO2021260582A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
| TW202216208A (zh) * | 2020-06-24 | 2022-05-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及atr抑制劑之組合 |
| CN115515644A (zh) * | 2020-06-28 | 2022-12-23 | 昆山新蕴达生物科技有限公司 | 一种抗体-药物偶联物，其制备方法及应用 |
| AU2021308190A1 (en) * | 2020-07-13 | 2023-02-02 | Regeneron Pharmaceuticals, Inc. | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
| KR102349925B1 (ko) * | 2020-07-16 | 2022-01-12 | 주식회사 피노바이오 | Fl118 약물을 포함하는 화합물 및 이를 이용한 면역접합체 |
| JPWO2022019259A1 (cg-RX-API-DMAC10.html) * | 2020-07-20 | 2022-01-27 | ||
| JP2023537051A (ja) * | 2020-08-13 | 2023-08-30 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 抗体薬物複合体 |
| EP4211598B1 (en) | 2020-09-12 | 2026-01-07 | AstraZeneca UK Limited | A scoring method for an anti-her2 antibody-drug conjugate therapy |
| CA3170019A1 (en) * | 2020-09-15 | 2022-03-24 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | A camptothecin drug and its antibody conjugate thereof |
| TW202214230A (zh) * | 2020-09-30 | 2022-04-16 | 大陸商映恩生物製藥（蘇州）有限公司 | 一種抗腫瘤化合物及其製備方法和應用 |
| IL301921A (en) | 2020-10-09 | 2023-06-01 | Daiichi Sankyo Co Ltd | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| WO2022078260A1 (zh) * | 2020-10-12 | 2022-04-21 | 四川百利药业有限责任公司 | 一种喜树碱类衍生物及其配体-药物偶联物 |
| AU2021361938A1 (en) * | 2020-10-12 | 2023-05-25 | Systimmune, Inc. | Deuterated camptothecin derivative and antibody-drug conjugate thereof |
| KR20230106645A (ko) | 2020-11-11 | 2023-07-13 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트와 항 SIRPα 항체의 조합 |
| WO2022102695A1 (ja) | 2020-11-12 | 2022-05-19 | 第一三共株式会社 | 抗ｂ７－ｈ３抗体－薬物コンジュゲート投与による中皮腫の治療 |
| CN112535738B (zh) * | 2020-12-04 | 2022-09-09 | 中国科学技术大学 | 奥沙利铂偶联物及其制备方法和应用 |
| AU2021394411A1 (en) * | 2020-12-11 | 2023-07-06 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Novel camptothecin derivative, composition containing same, and use thereof |
| EP4277665A1 (en) * | 2021-01-13 | 2023-11-22 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
| CN116888123A (zh) * | 2021-02-09 | 2023-10-13 | 微境生物医药科技(上海)有限公司 | 用于adc制备的喜树碱衍生物 |
| CN117015549A (zh) * | 2021-03-17 | 2023-11-07 | 江苏恒瑞医药股份有限公司 | 一种喜树碱衍生物的制备方法 |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| CN116867789B (zh) * | 2021-03-31 | 2025-06-24 | 上海复旦张江生物医药股份有限公司 | 一种伊喜替康衍生物的制备方法及其中间体 |
| MX2023012060A (es) | 2021-04-13 | 2024-01-22 | Nuvalent Inc | Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr. |
| US20250101032A1 (en) * | 2021-05-07 | 2025-03-27 | ALX Oncology Inc. | Exatecan derivatives and antibody-drug conjugates thereof |
| CN113402584A (zh) * | 2021-07-06 | 2021-09-17 | 联宁（苏州）生物制药有限公司 | 一种抗体偶联药物连接子的中间体lnd1067-l1的合成方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| MX2024006039A (es) | 2021-11-18 | 2024-06-04 | Astrazeneca Uk Ltd | Combinacion de conjugado de anticuerpo-farmaco e inhibidor selectivo de poli(adenosina-5'-difosfato-ribosa) polimerasa 1 (parp1). |
| MX2024007498A (es) | 2021-12-16 | 2024-09-04 | Mabwell Shanghai Bioscience Co Ltd | Compuesto de camptotecina y conjuado del mismo. |
| JP2025503511A (ja) * | 2021-12-28 | 2025-02-04 | アストラゼネカ ユーケー リミテッド | 抗体－薬物コンジュゲート及びｒａｓｇ１２ｃ阻害剤の組み合わせ |
| AU2022429904A1 (en) | 2021-12-28 | 2024-06-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atr inhibitor |
| JP2025509564A (ja) | 2022-03-16 | 2025-04-11 | アストラゼネカ ユーケー リミテッド | 抗ｔｒｏｐ２抗体－薬物コンジュゲート治療のためのスコアリング方法 |
| TW202400140A (zh) | 2022-04-27 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合 |
| US20250296966A1 (en) | 2022-05-11 | 2025-09-25 | Daiichi Sankyo Company, Limited | Combination of an antibody specific for a tumor antigen and a cd47 inhibitor |
| IL318313A (en) | 2022-07-12 | 2025-03-01 | Cytomx Therapeutics Inc | EPCAM antibody conjugates and their uses |
| TW202412859A (zh) | 2022-07-28 | 2024-04-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及雙特異性檢查點抑制劑之組合 |
| CN117024438A (zh) * | 2022-07-29 | 2023-11-10 | 杭州爱科瑞思生物医药有限公司 | 依沙替康衍生物及其应用 |
| AU2023319535A1 (en) | 2022-08-02 | 2025-02-27 | Nona Biosciences (Suzhou) Co., Ltd. | Msln antibody-drug conjugate |
| CA3265870A1 (en) * | 2022-09-02 | 2024-03-07 | Merck Sharp & Dohme Llc | Pharmaceutical compositions based on topoisomerase-1 inhibitors derived from Exatecan, and their uses |
| EP4608453A1 (en) * | 2022-10-25 | 2025-09-03 | Merck Sharp & Dohme LLC | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
| CN116712561A (zh) * | 2022-12-29 | 2023-09-08 | 杭州爱科瑞思生物医药有限公司 | 含n-亚甲基酰胺连接子的抗体-药物偶联物 |
| EP4653018A1 (en) | 2023-01-18 | 2025-11-26 | Medilink Therapeutics (Suzhou) Co., Ltd. | Antibody drug conjugate as well as preparation method therefor and use thereof |
| EP4655006A2 (en) | 2023-01-25 | 2025-12-03 | Immunome, Inc. | Exatecan immunoconjugates |
| KR20250150111A (ko) * | 2023-02-23 | 2025-10-17 | 프론트라인 바이오파마(항저우) 컴퍼니 리미티드 | 캄프토테신 유도체 및 이의 접합체, 이의 제조 방법 및 의학적 용도 |
| AU2024236246A1 (en) | 2023-03-14 | 2025-10-30 | Daiichi Sankyo Company, Limited | Combination of anti-CDH6 antibody-drug conjugate and VEGF inhibitor |
| CN118666946A (zh) * | 2023-03-15 | 2024-09-20 | 上海亲合力生物医药科技股份有限公司 | 连接子及使用其的偶联药物、抗体偶联药物及其应用 |
| IL320593A (en) | 2023-03-29 | 2025-07-01 | Daiichi Sankyo Co Ltd | Anti-CD25 antibody and anti-CD25 antibody conjugate |
| KR20250173601A (ko) | 2023-03-31 | 2025-12-10 | 다이이찌 산쿄 가부시키가이샤 | 항 CDH6 항체-약물 콘주게이트와 HIF-2α 저해제의 조합 |
| TW202506190A (zh) | 2023-04-05 | 2025-02-16 | 日商第一三共股份有限公司 | 利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法 |
| TW202446421A (zh) | 2023-04-10 | 2024-12-01 | 日商第一三共股份有限公司 | 抗ｂ７－ｈ３抗體－藥物結合物與ａｔｒ抑制劑或ａｔｍ抑制劑之組合 |
| KR20250163373A (ko) | 2023-04-11 | 2025-11-20 | 바이오레이 파마슈티컬 씨오., 엘티디. | 항-ror1 항체 및 그 약물 접합체 |
| KR20250175330A (ko) | 2023-04-19 | 2025-12-16 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트와 다른 약제의 조합 |
| WO2025019254A1 (en) | 2023-07-14 | 2025-01-23 | Guardant Health, Inc. | Classification of breast tumors using dna methylation from liquid biopsy |
| TW202506196A (zh) * | 2023-07-28 | 2025-02-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 含有糖皮質激素的抗體藥物偶聯物的藥物組合物 |
| CN119490559A (zh) * | 2023-08-16 | 2025-02-21 | 中山康方生物医药有限公司 | 化合物以及含有该化合物的抗体偶联药物 |
| WO2025054707A1 (en) * | 2023-09-11 | 2025-03-20 | Theratechnologies Inc. | Peptide conjugates of camptothecin analogs and uses thereof |
| WO2025054996A1 (en) * | 2023-09-15 | 2025-03-20 | Duality Biologics (Suzhou) Co., Ltd. | Antibody-drug conjugate |
| CN117417347A (zh) * | 2023-09-28 | 2024-01-19 | 杭州爱科瑞思生物医药有限公司 | 卤素取代的依沙替康的酰胺衍生物及其制备方法和应用 |
| WO2025078841A2 (en) | 2023-10-11 | 2025-04-17 | Antikor Biopharma Limited | Antibodies, conjugates, and uses thereof |
| TW202523359A (zh) | 2023-10-24 | 2025-06-16 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合 |
| WO2025120513A1 (en) | 2023-12-05 | 2025-06-12 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor |
| WO2025176180A1 (zh) * | 2024-02-23 | 2025-08-28 | 江苏恒瑞医药股份有限公司 | 艾日布林衍生物药物偶联物用于治疗肿瘤的用途 |
| WO2025209545A1 (zh) * | 2024-04-03 | 2025-10-09 | 上海药明合联生物技术有限公司 | 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物 |
| WO2025238587A1 (en) | 2024-05-16 | 2025-11-20 | Daiichi Sankyo Company, Limited | Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor |
| WO2025242090A1 (zh) * | 2024-05-21 | 2025-11-27 | 康诺亚生物医药科技（成都）有限公司 | 喜树碱衍生物及其中间体的制备方法 |
| WO2025252189A1 (zh) * | 2024-06-06 | 2025-12-11 | 海思科医药集团股份有限公司 | 喜树碱类衍生物及其用途 |
| WO2026025013A2 (en) | 2024-07-26 | 2026-01-29 | Pfizer Inc. | Combination therapy using cdk4 inhibitors for cancer treatments |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JP3008226B2 (ja) | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| US5658920A (en) | 1991-01-16 | 1997-08-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| JP3507073B2 (ja) | 1992-03-24 | 2004-03-15 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的結合対の成員の製造方法 |
| JP3359955B2 (ja) | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
| US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
| JPH08337584A (ja) | 1995-04-10 | 1996-12-24 | Dai Ichi Seiyaku Co Ltd | 縮合六環式アミノ化合物、これを含有する医薬及びその製法 |
| SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| CA2192725C (en) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| JPH1095802A (ja) | 1995-12-28 | 1998-04-14 | Tanabe Seiyaku Co Ltd | カンプトテシン誘導体 |
| TW527183B (en) * | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
| JPH1171280A (ja) | 1997-06-26 | 1999-03-16 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| JPH1192405A (ja) | 1997-09-19 | 1999-04-06 | Dai Ichi Seiyaku Co Ltd | 薬物複合体 |
| US6602684B1 (en) | 1998-04-20 | 2003-08-05 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| EP1080732A4 (en) * | 1998-05-22 | 2004-08-25 | Daiichi Seiyaku Co | DRUG COMPOSITION |
| AU765409B2 (en) | 1998-10-30 | 2003-09-18 | Daiichi Pharmaceutical Co., Ltd. | DDS compounds and method for assaying the same |
| EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| SI2283867T1 (sl) | 1999-06-25 | 2014-07-31 | Immunogen, Inc. | Metode zdravljenja z majtanzinoidom konjugiranim protitelesom anti-ErbB |
| HU230586B1 (hu) | 1999-06-25 | 2017-02-28 | Genentech, Inc. | Anti-ErbB antitest/maytansinoid konjugátumok alkalmazása rákos betegségek kezelésére szolgáló gyógyszer előállítására |
| JP2002060351A (ja) | 2000-03-22 | 2002-02-26 | Dai Ichi Seiyaku Co Ltd | 水酸基を有する薬物を含むｄｄｓ化合物 |
| CA2412582A1 (en) | 2000-06-29 | 2002-01-03 | Daiichi Pharmaceutical Co., Ltd. | Dds compound and process for the preparation thereof |
| CA2415922A1 (en) | 2000-07-13 | 2002-01-24 | Daiichi Pharmaceutical Co., Ltd. | Pharmaceutical compositions containing dds compound |
| EP3690043A1 (en) | 2000-10-06 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Antibody composition-producing cell |
| TWI313609B (en) | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
| KR100573565B1 (ko) | 2001-08-29 | 2006-04-25 | 주식회사 포스코 | 요철부가 형성된 실린더 링과 이 실린더 링이 결합된 맨드릴 |
| RU2313368C2 (ru) | 2001-11-01 | 2007-12-27 | Ю Эй Би Рисерч Фаундейшн | Комбинации антител, обладающих селективностью по отношению к рецептору лиганда, индуцирующему апоптоз, ассоциированный с фактором некроза опухоли, и других терапевтических средств |
| AU2002363939A1 (en) | 2001-11-20 | 2003-06-10 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| US7585491B2 (en) | 2002-12-13 | 2009-09-08 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
| US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| JP4942643B2 (ja) | 2004-03-02 | 2012-05-30 | シアトル ジェネティックス， インコーポレイテッド | 部分的に付加された抗体およびそれらの結合体化方法 |
| CA2564076C (en) | 2004-05-19 | 2014-02-18 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| EP1753463A2 (en) | 2004-06-01 | 2007-02-21 | Genentech, Inc. | Antibody drug conjugates and methods |
| KR20150043558A (ko) * | 2004-07-22 | 2015-04-22 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| RU2438705C2 (ru) | 2005-01-21 | 2012-01-10 | Дженентек, Инк. | Введение фиксированных доз her-антител |
| DE102005009084A1 (de) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel |
| DE102005009099A1 (de) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Camptothecin-Peptid-Derivate und diese enthaltende Arzneimittel |
| US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| WO2007100385A2 (en) | 2005-10-31 | 2007-09-07 | Genentech, Inc. | Macrocyclic depsipeptide antibody-drug conjugates and methods |
| US20080131428A1 (en) | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| UA95958C2 (en) | 2006-05-30 | 2011-09-26 | Дженентек, Инк. | Antibody that binds to cd22, immunoconjugates and uses therefor |
| SG172656A1 (en) | 2006-05-30 | 2011-07-28 | Genentech Inc | Antibodies and immunoconjugates and uses therefor |
| ITMI20061473A1 (it) | 2006-07-26 | 2008-01-27 | Indena Spa | Derivati della camptotecina ad attivita antitumorale |
| AU2009225877B2 (en) * | 2008-03-18 | 2014-11-20 | Genentech, Inc. | Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| MY197840A (en) * | 2008-04-30 | 2023-07-20 | Immunogen Inc | Cross-linkers and their uses |
| JP5539971B2 (ja) * | 2008-05-13 | 2014-07-02 | ジェネンテック， インコーポレイテッド | ビーズに基づく親和性キャプチャおよび質量分析による抗体薬剤コンジュゲートの分析 |
| JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| DK2396036T3 (en) | 2009-02-13 | 2017-10-16 | Immunomedics Inc | Immune conjugates with an intracellular cleavable compound |
| SG10201507044PA (en) | 2009-05-29 | 2015-10-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| KR20120104158A (ko) * | 2009-07-22 | 2012-09-20 | 엔즌 파마슈티칼스, 인코포레이티드 | 7-에틸-10-히드록시캠토테신의 다분지형 중합 컨쥬게이트와 ｈｅｒ２ 수용체 길항제를 병용하여 ｈｅｒ２ 양성 암을 치료하는 방법 |
| US20110042149A1 (en) | 2009-08-18 | 2011-02-24 | Baker Hughes Incorporated | Methods of forming polycrystalline diamond elements, polycrystalline diamond elements, and earth-boring tools carrying such polycrystalline diamond elements |
| EP2480230A4 (en) | 2009-09-24 | 2015-06-10 | Seattle Genetics Inc | DR5 Ligand-HEILMITTELKONJUGATE |
| IN2012DN03354A (cg-RX-API-DMAC10.html) | 2009-12-02 | 2015-10-23 | Immunomedics Inc | |
| CN103079587B (zh) | 2010-05-13 | 2016-05-11 | 印第安纳大学研究及科技有限公司 | 呈现核激素受体活性的胰高血糖素超家族肽 |
| US9062100B2 (en) | 2010-05-17 | 2015-06-23 | Livtech, Inc. | Anti-human TROP-2 antibody having anti-tumor activity in vivo |
| US20110300150A1 (en) | 2010-05-18 | 2011-12-08 | Scott Eliasof | Compositions and methods for treatment of autoimmune and other disease |
| EP2594589A1 (en) | 2010-06-10 | 2013-05-22 | Sapporo Medical University | ANTI-Trop-2 ANTIBODY |
| EP2593142B8 (en) * | 2010-07-12 | 2018-12-26 | Pfizer Healthcare Ireland | Multifunctional antibody conjugates |
| WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
| JP6014596B2 (ja) | 2010-11-09 | 2016-10-25 | メディミューン，エルエルシー | 均一コンジュゲーションのための抗体足場 |
| JP5889912B2 (ja) | 2010-11-17 | 2016-03-22 | ジェネンテック， インコーポレイテッド | アラニニルメイタンシノール抗体コンジュゲート |
| CA2854720C (en) | 2011-11-11 | 2018-12-18 | Rinat Neuroscience Corp. | Antibodies specific for trop-2 and their uses |
| US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| CA2859255A1 (en) * | 2011-12-14 | 2013-06-20 | Seattle Genetics, Inc. | New antibody drug conjugates (adcs) and the use thereof |
| US20130280282A1 (en) | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
| MX2014015205A (es) | 2012-06-14 | 2015-08-14 | Ambrx Inc | Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear. |
| CN115960111A (zh) * | 2012-10-11 | 2023-04-14 | 第一三共株式会社 | 抗体－药物偶联物 |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| CN105051032B (zh) * | 2013-01-03 | 2017-08-15 | 赛特瑞恩股份有限公司 | 抗体‑连接子‑药物偶联物、其制法及包含其的抗癌药物组合物 |
| JP6130517B2 (ja) | 2013-12-25 | 2017-05-17 | 第一三共株式会社 | 抗ｔｒｏｐ２抗体−薬物コンジュゲート |
| PL4212552T3 (pl) * | 2014-01-31 | 2025-03-17 | Daiichi Sankyo Company, Limited | Koniugat przeciwciało anty-her2-lek |
| SI3129063T1 (sl) | 2014-04-10 | 2021-08-31 | Daiichi Sankyo Company | PROTI-HER3 konjugat zdravila s protitelescem |
-
2015
- 2015-01-28 PL PL22198821.5T patent/PL4212552T3/pl unknown
- 2015-01-28 KR KR1020227004389A patent/KR102417312B1/ko active Active
- 2015-01-28 KR KR1020237024073A patent/KR102606930B1/ko active Active
- 2015-01-28 SM SM20250030T patent/SMT202500030T1/it unknown
- 2015-01-28 KR KR1020207035147A patent/KR102238848B1/ko active Active
- 2015-01-28 PT PT15743738T patent/PT3101032T/pt unknown
- 2015-01-28 RS RS20211465A patent/RS62618B1/sr unknown
- 2015-01-28 DK DK18204861.1T patent/DK3466976T3/da active
- 2015-01-28 HR HRP20241783TT patent/HRP20241783T1/hr unknown
- 2015-01-28 SG SG10201800210TA patent/SG10201800210TA/en unknown
- 2015-01-28 PH PH1/2020/552271A patent/PH12020552271A1/en unknown
- 2015-01-28 SM SM20190211T patent/SMT201900211T1/it unknown
- 2015-01-28 LT LTEP18204861.1T patent/LT3466976T/lt unknown
- 2015-01-28 KR KR1020237040108A patent/KR102881140B1/ko active Active
- 2015-01-28 CN CN201910768778.XA patent/CN110464847B/zh active Active
- 2015-01-28 KR KR1020217009854A patent/KR102275925B1/ko active Active
- 2015-01-28 LT LTEP15743738.5T patent/LT3101032T/lt unknown
- 2015-01-28 SM SM20210659T patent/SMT202100659T1/it unknown
- 2015-01-28 PT PT18204861T patent/PT3466976T/pt unknown
- 2015-01-28 DK DK15743738.5T patent/DK3101032T3/en active
- 2015-01-28 HU HUE18204861A patent/HUE057464T2/hu unknown
- 2015-01-28 KR KR1020217021044A patent/KR102314913B1/ko active Active
- 2015-01-28 CA CA2928794A patent/CA2928794C/en active Active
- 2015-01-28 SI SI201530587T patent/SI3101032T1/sl unknown
- 2015-01-28 EP EP24202881.9A patent/EP4464707A3/en active Pending
- 2015-01-28 RS RS20241442A patent/RS66412B1/sr unknown
- 2015-01-28 KR KR1020237008409A patent/KR102557062B1/ko active Active
- 2015-01-28 CN CN201580003121.4A patent/CN105829346B/zh active Active
- 2015-01-28 HR HRP20211848TT patent/HRP20211848T1/hr unknown
- 2015-01-28 AU AU2015212265A patent/AU2015212265B2/en active Active
- 2015-01-28 ES ES18204861T patent/ES2895254T3/es active Active
- 2015-01-28 KR KR1020167015961A patent/KR101916553B1/ko active Active
- 2015-01-28 HU HUE15743738 patent/HUE044389T2/hu unknown
- 2015-01-28 ES ES15743738T patent/ES2727351T3/es active Active
- 2015-01-28 JP JP2015542503A patent/JP5998289B2/ja active Active
- 2015-01-28 PL PL18204861T patent/PL3466976T3/pl unknown
- 2015-01-28 HU HUE22198821A patent/HUE070620T2/hu unknown
- 2015-01-28 PL PL15743738T patent/PL3101032T3/pl unknown
- 2015-01-28 RS RS20190280A patent/RS58415B1/sr unknown
- 2015-01-28 EP EP18204861.1A patent/EP3466976B1/en active Active
- 2015-01-28 WO PCT/JP2015/000355 patent/WO2015115091A1/ja not_active Ceased
- 2015-01-28 KR KR1020217032820A patent/KR102362920B1/ko active Active
- 2015-01-28 PT PT221988215T patent/PT4212552T/pt unknown
- 2015-01-28 MX MX2016006498A patent/MX375930B/es active IP Right Grant
- 2015-01-28 NZ NZ719202A patent/NZ719202A/en unknown
- 2015-01-28 BR BR112016013482-6A patent/BR112016013482B1/pt active IP Right Grant
- 2015-01-28 HR HRP20190431TT patent/HRP20190431T1/hr unknown
- 2015-01-28 KR KR1020227022459A patent/KR102465042B1/ko active Active
- 2015-01-28 EP EP21187152.0A patent/EP3973995A1/en not_active Withdrawn
- 2015-01-28 KR KR1020227038845A patent/KR102510128B1/ko active Active
- 2015-01-28 SI SI201531748T patent/SI3466976T1/sl unknown
- 2015-01-28 EP EP15743738.5A patent/EP3101032B1/en active Active
- 2015-01-28 LT LTEP22198821.5T patent/LT4212552T/lt unknown
- 2015-01-28 ES ES22198821T patent/ES3005311T3/es active Active
- 2015-01-28 FI FIEP22198821.5T patent/FI4212552T3/fi active
- 2015-01-28 EP EP22198821.5A patent/EP4212552B1/en active Active
- 2015-01-28 SI SI201532047T patent/SI4212552T1/sl unknown
- 2015-01-28 KR KR1020187031594A patent/KR102190548B1/ko active Active
- 2015-01-28 DK DK22198821.5T patent/DK4212552T3/da active
- 2015-01-28 IL IL278891A patent/IL278891B2/en unknown
- 2015-01-28 SG SG11201603960XA patent/SG11201603960XA/en unknown
- 2015-01-28 KR KR1020257036448A patent/KR20250162923A/ko active Pending
- 2015-01-30 TW TW111122223A patent/TWI796244B/zh active
- 2015-01-30 TW TW107116039A patent/TWI661839B/zh active
- 2015-01-30 TW TW104103127A patent/TWI627967B/zh active
- 2015-01-30 TW TW111122225A patent/TWI796246B/zh active
- 2015-01-30 TW TW110104664A patent/TWI789700B/zh active
- 2015-01-30 TW TW113121616A patent/TWI870307B/zh active
- 2015-01-30 TW TW108114649A patent/TWI722422B/zh active
- 2015-01-30 TW TW112104986A patent/TWI848560B/zh active
- 2015-01-30 TW TW111122224A patent/TWI796245B/zh active
- 2015-01-30 TW TW111122222A patent/TWI796243B/zh active
-
2016
- 2016-04-21 IL IL245252A patent/IL245252B/en active IP Right Grant
- 2016-04-22 ZA ZA2016/02802A patent/ZA201602802B/en unknown
- 2016-05-16 PH PH12016500904A patent/PH12016500904A1/en unknown
- 2016-05-18 MX MX2020010682A patent/MX2020010682A/es unknown
- 2016-07-28 US US15/221,851 patent/US10155821B2/en active Active
- 2016-08-29 JP JP2016166850A patent/JP6046301B1/ja active Active
- 2016-11-16 JP JP2016222861A patent/JP6466895B2/ja active Active
-
2017
- 2017-01-13 JP JP2017003826A patent/JP6105183B1/ja active Active
-
2018
- 2018-09-13 US US16/130,615 patent/US11795236B2/en active Active
-
2019
- 2019-01-10 JP JP2019002311A patent/JP6665325B2/ja active Active
- 2019-04-11 CY CY20191100406T patent/CY1121573T1/el unknown
- 2019-05-21 IL IL266790A patent/IL266790A/en active IP Right Grant
-
2020
- 2020-01-29 AU AU2020200596A patent/AU2020200596B2/en active Active
- 2020-02-19 JP JP2020025886A patent/JP6914380B2/ja active Active
- 2020-08-19 US US16/997,613 patent/US11584800B2/en active Active
-
2021
- 2021-07-06 NO NO2021027C patent/NO2021027I1/no unknown
- 2021-07-06 HU HUS2100025C patent/HUS2100025I1/hu unknown
- 2021-07-07 CY CY2021018C patent/CY2021018I1/el unknown
- 2021-07-12 FR FR21C1030C patent/FR21C1030I2/fr active Active
- 2021-07-13 LT LTPA2021515C patent/LTC3101032I2/lt unknown
- 2021-07-13 JP JP2021115436A patent/JP7146031B2/ja active Active
- 2021-07-16 NL NL301117C patent/NL301117I2/nl unknown
- 2021-11-30 CY CY20211101037T patent/CY1124774T1/el unknown
-
2022
- 2022-06-02 AU AU2022203818A patent/AU2022203818B2/en active Active
- 2022-09-20 JP JP2022149242A patent/JP7467557B2/ja active Active
-
2023
- 2023-09-12 US US18/367,446 patent/US20240026030A1/en active Pending
-
2024
- 2024-01-29 IL IL310627A patent/IL310627B1/en unknown
- 2024-04-03 JP JP2024059913A patent/JP7703727B2/ja active Active
-
2025
- 2025-06-25 JP JP2025107304A patent/JP2025138756A/ja active Pending
- 2025-10-29 IL IL324322A patent/IL324322A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017095457A5 (cg-RX-API-DMAC10.html) | ||
| FI4212552T3 (fi) | Anti-her2-vasta-aine-lääkeainekonjugaatti | |
| ES2966473T3 (es) | Derivados de camptotecina | |
| IL266563B (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| JPWO2020027100A5 (cg-RX-API-DMAC10.html) | ||
| NZ758176A (en) | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | |
| JP2019502746A5 (cg-RX-API-DMAC10.html) | ||
| JP2018504379A5 (cg-RX-API-DMAC10.html) | ||
| JP2014528480A5 (cg-RX-API-DMAC10.html) | ||
| JP2021503450A5 (cg-RX-API-DMAC10.html) | ||
| JP2018537975A5 (cg-RX-API-DMAC10.html) | ||
| JP2020526584A5 (cg-RX-API-DMAC10.html) | ||
| HRP20211710T1 (hr) | Konjugacija specifična za mjesto spajanja lijekova za povezivanje s protutijelima i konjugati protutijela u lijeku koji nastaje kao rezultat | |
| HRP20231609T1 (hr) | Konjugati lijeka koji sadrže antitijela protiv klaudina 18.2 | |
| JP2019501204A5 (cg-RX-API-DMAC10.html) | ||
| JP2017536340A5 (cg-RX-API-DMAC10.html) | ||
| JP2018508572A5 (cg-RX-API-DMAC10.html) | ||
| FI3345613T3 (fi) | Koostumus käytettäväksi syövän tai angiogeneesiin liittyvän sairauden hoidossa käsittäen tuumoriin penetroituvan peptidin ja VEGF-estäjän fuusioproteiinin | |
| HRP20211164T1 (hr) | Derivati hemiasterlina za konjugaciju i terapiju | |
| JP2017536344A5 (cg-RX-API-DMAC10.html) | ||
| TR201802090T4 (tr) | Kanserin tedavisine yönelik monoklonal anti-GT468 antikorlar. | |
| IL273387B1 (en) | Thylanstatin analogs | |
| JPWO2021055295A5 (cg-RX-API-DMAC10.html) | ||
| JP2021503915A5 (cg-RX-API-DMAC10.html) | ||
| JP2010518158A5 (cg-RX-API-DMAC10.html) |